Almac Group Appoints Two Marketing Directors
Almac Group recently appointed two key positions in marketing: Market Development Director, and Senior Market Insight Director.
Almac Group, a pharmaceutical contract development and manufacturing organization, has created two new positions to expand their global marketing team.
Matt Cocking has been appointed market development director for the Clinical Technologies business unit. This position was created to help develop the marketing plan to keep in line with the company’s business strategy. Cocking comes from the clinical trial software solutions company, Y Prime, with over 10 years of experience as a senior marketing leader.
Laura Montgomery will also be joining the Almac Group as the senior market insight director. Montgomery will be responsible for developing, delivering, and communicating actionable market research to assist Almac Group in making data-driven decisions. Montgomery was previously the project director for a healthcare market research consultancy, Adelphi Research.
Source: Almac
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
